Navigation Links
OncoGenex Reports Third Quarter Financial Results
Date:11/10/2008

cently filed Quarterly Report on Form 10-Q. No assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on the results of operations or financial condition of the Company. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof.

Condensed Statements of Operations

(Unaudited)

(in thousands)

Three Months Nine Months

Ended Ended

September 30, September 30,

2008 2007 2008 2007

Operating expenses

Research and development $ 1,639 $ 1,094 $ 3,621 $ 3,075

General and administrative 1,024 609 2,243 2,709

------------------- -------------------

Total operating expenses 2,663 1,703 5,864 5,784

------------------- -------------------

Other income (expense) 297 (27) 88 44

------------------- -------------------

Loss for the period before taxes (2,366) (1,730) (5,776) (5,740)

Income tax expense (recovery) (2,515) 200 (2,100) 573

------------------- -------------------

Operating income (loss) before

extraordinary gain 149 (1,930) (3,676) (6,313)

Extraordinary gain 4,428 - 4,428 -

-------------------
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 2013 Patheon Inc ., a ... the global pharmaceutical industry, will host a complimentary webinar ... Testing” on Tuesday, June 4, 2013 at 11 a.m. ... required to comply with regulations for cleaning validation. ... scientific underpinning and little evaluation of risk. Some ...
(Date:5/23/2013)... May 23, 2013 VG Energy, an ... with DAK Renewable Research to conduct field trials ... VG Energy is a majority owned subsidiary of ... VG Energy,s exclusively licensed compound LipidMax selectively ... yield in plants, possessing a wide variety of ...
(Date:5/23/2013)... Ill. , May 23, 2013 Z ... providing value-added ingredients to a variety of industries, announced ... in a panel discussion at this year,s National Restaurant ... 20-21, 2013, on behalf of the Research Chefs Association.  ... for Restaurants: The Good, the Bad and the Ugly," ...
(Date:5/23/2013)... 2013 During the conduct of ... adhere to principles of good clinical practice (GCP) ... Dr. Jeremy Lim, Fellow, Clinical Development at Novartis ... ,     Understand the International Conference on Harmonization (ICH) ... regulations for the conduction of clinical trials , ...
Breaking Biology Technology:Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing” 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 3Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 2Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 3Adhering to Good Clinical Practice, New Webinar Hosted by Xtalks 2
... K Chakrabarti and Raghavendra G Mirmira*, Departments of Medicine , ... of Virginia Health Sciences Center, 450 Ray C Hunt Dr, Box 801407, ... *Corresponding author , ... The chromatin immunoprecipitation (ChIP) assay has been used in recent ...
... Margaret Saha, Department of Biology, College of William, ... , Introduction , ... genetic research. Recently, , the use of ... small research laboratory settings. However, the success of automated , ...
... Hans-Peter Horz, Ph.D.1, Richard Kurtz, Ph.D.2, David Batey, Ph.D.2 , ... 1Department of Biological Sciences, Stanford University, Stanford, CA , ... Incorporated, South San Francisco, CA , , ... The levels of the amoA gene were used to measure the ammonia-oxidizing ...
Cached Biology Technology:Quantitative Analysis of Protein-DNA Associations in Vivo Using Real-Time PCR, Rev A 2Quantitative Analysis of Protein-DNA Associations in Vivo Using Real-Time PCR, Rev A 3Quantitative Analysis of Protein-DNA Associations in Vivo Using Real-Time PCR, Rev A 4Quantitative Analysis of Protein-DNA Associations in Vivo Using Real-Time PCR, Rev A 5Quantitative Analysis of Protein-DNA Associations in Vivo Using Real-Time PCR, Rev A 6Quantitative Analysis of Protein-DNA Associations in Vivo Using Real-Time PCR, Rev A 7Quantitative Analysis of Protein-DNA Associations in Vivo Using Real-Time PCR, Rev A 8Quantitation of DNA for Automated Sequencing Using the VersaFluor Fluorometer 2Quantitation of DNA for Automated Sequencing Using the VersaFluor Fluorometer 3Monitoring Microbial Populations Using Real-Time qPCR on the MJ Research Opticon 2 System 2Monitoring Microbial Populations Using Real-Time qPCR on the MJ Research Opticon 2 System 3Monitoring Microbial Populations Using Real-Time qPCR on the MJ Research Opticon 2 System 4Monitoring Microbial Populations Using Real-Time qPCR on the MJ Research Opticon 2 System 5Monitoring Microbial Populations Using Real-Time qPCR on the MJ Research Opticon 2 System 6Monitoring Microbial Populations Using Real-Time qPCR on the MJ Research Opticon 2 System 7
(Date:5/23/2013)... estrogen suppresses lipid synthesis in the liver, UC Irvine ... certain liver diseases. , With this finding, Dr. ... views in the field. Study results appear in the ... . , "The dogma in the steroid receptor field ... in the nucleus respond to steroid hormones by regulating ...
(Date:5/23/2013)... have succeeded in treating cerebral palsy with autologous cord ... a 2.5 year old boy had been in a ... Just two months after treatment with the cord blood ... following months, the child learned to speak simple sentences ... a Korean study, dispel the long-held doubts about the ...
(Date:5/22/2013)... YORK CITY, May 22, 2013 U.S. Forest Service ... team that, with funding from the TKF Foundation, will ... help communities and individuals recover from tragedy. , The ... one of six projects selected for grant funding. In ... and sacred spaces in recovery and resiliency, the 3-year, ...
Breaking Biology News(10 mins):UCI study reveals new mechanism for estrogen suppression of liver lipid synthesis 2First successful treatment of pediatric cerebral palsy with autologous cord blood 2'Landscapes of Resilience' to study how people use nature as a source of recovery 2
... the standard emergency treatment in the U.S. for ... Diego bioengineering researchers have reported improved resuscitation with ... in humans that have shown benefits of intravenous ... saline, the researchers combined hypertonic saline with viscosity ...
... and fast-growing world of nanotechnology, researchers are continually on ... and discovery to scales much smaller than the tiniest ... at Arizona State University, researchers are using DNA to ... great potential for advancing medical and electronic applications. DNA, ...
... like nothing on today,s Earth. But the ecology of ... first study to reconstruct detailed food webs for ancient ... journal PLoS Biology, suggests that networks of feeding relationships ... years ago are remarkably similar to those of today. ...
Cached Biology News:Hyperviscous fluids: Better treatment for severe blood loss 2Hyperviscous fluids: Better treatment for severe blood loss 3Hyperviscous fluids: Better treatment for severe blood loss 4Scientists make chemical cousin of DNA for use as new nanotechnology building block 2Scientists make chemical cousin of DNA for use as new nanotechnology building block 3Ancient ecosystems organized much like our own 2Ancient ecosystems organized much like our own 3
BD BioCoat Fibronectin 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of human fibronectin....
... to Human Cytokeratin TYPE II Reacts ... keratins. Including epidermal cell keratin of 86 ... and 67kD. Broad keratin reactivity is found ... Immunogen: Human epidermal ...
BD BioCoat Fibronectin 150 mm Culture Dishes...
... new product number, created to easily match ... yet, please order under the old Sigma-Aldrich ... assistance. ID clarifier: tissue-culture treated ... cm 2 D H 245 ...
Biology Products: